October 23, 2025

Waist Loss Only Part of Semaglutide’s Power

Semaglutide lowered cardiovascular events in patients with overweight or obesity without diabetes, independent of weight loss.

Conexiant

October 23, 2025

Sex-Stratified Genome Analysis Maps Depression Variants

X-chromosome variant and higher heritability distinguish male and female depression genetics.

Conexiant

October 23, 2025

Nutritional IBD screening tools ranked

Single-center cohort finds MIRT most sensitive at predicting malnutrition or low Fat-Free Mass Index within six months in patients in remission with IBD; SaskIBD-NR shows the highest accuracy for GLIM-defined malnutrition and for low Fat-Free Mass Index.

Conexiant

October 22, 2025

Primary Care Workload: 62 Hours Weekly

Electronic records detail physician work hours across multiple primary care clinics.

Conexiant

October 22, 2025

Do GLP-1RAs Differ in Cardiometabolic Protection?

Researchers found that liraglutide and semaglutide offer similar cardiovascular and kidney benefits in type 2 diabetes.

Conexiant

October 21, 2025

UCI Health takes national lead in combating diabetes epidemic

With diabetes rates soaring, UCI Health launches a bold initiative to improve care, reduce disparities, and protect vulnerable communities.

UCI Health

October 20, 2025

FDA Okays First Oral GLP-1 for CV Risk

Novo Nordisk’s once-daily GLP-1 tablet reduced major adverse cardiovascular events in high-risk adults, including those without prior heart attack or stroke.

Conexiant

October 20, 2025

Insights into the GLP-1 Landscape

From compounding to new opportunities, we look at some of the insights shared at an AAPS workshop

The Medicine Maker

October 16, 2025

Comprehensive Review Identifies Key Neonatal Death Risks

Review grades evidence on neonatal mortality across 64 reviews; methods and gaps outlined.

Conexiant